Document Detail


Optimized threshold for serum HCV RNA to predict treatment outcomes in hepatitis C patients receiving peginterferon alfa-2a/ribavirin.
MedLine Citation:
PMID:  23043383     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Summary.  It is unclear whether the current threshold for 'high' hepatitis C virus (HCV) RNA level (800 000 IU/mL) is optimal for predicting sustained virological response (SVR). We retrospectively analysed pretreatment HCV RNA levels and SVR rates in 1529 mono-infected and 176 HIV-HCV co-infected patients treated with peginterferon alfa-2a (40 kD) plus ribavirin. We improved the threshold for differentiating low and high viral load by fitting semiparametric generalized additive logistic regression models to the data and constructing receiver operating characteristics curves. Among HCV genotype 1 mono-infected patients, the difference in SVR rates between those with low and high baseline HCV RNA levels was 27% (70%vs 43%) when 400 000 IU/mL was used and 16% (59%vs 43%) when 800 000 IU/mL was used. In HIV-HCV genotype 1 co-infected patients, the difference was 51% (71%vs 20%) when 400 000 IU/mL was used and 43% (61%vs 18%) when 800 000 IU/mL was used. A lower threshold (200 000 IU/mL) was identified for genotype 1 mono-infected patients with 'normal' alanine aminotransferase (ALT) levels. No threshold could be identified in HCV genotype 2 or 3 patients. A threshold HCV RNA level of 400 000 IU/mL is optimal for differentiating high and low probability of SVR in genotype 1-infected individuals with elevated ALT.
Authors:
S Zeuzem; M Rodríguez-Torres; K Rajender Reddy; P Marcellin; M Diago; A Craxi; P Pockros; M Rizzetto; D Bernstein; M L Shiffman; A Lin; F Tatsch; S Hadziyannis
Related Documents :
23797543 - Social and environmental factors associated with the hospitalization of tuberculosis pa...
23740193 - Hepatitis b and c in switzerland - healthcare provider initiated testing for chronic he...
12462393 - Macrophage activation and hiv infection: can the trojan horse turn into a fortress?
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-5-14
Journal Detail:
Title:  Journal of viral hepatitis     Volume:  19     ISSN:  1365-2893     ISO Abbreviation:  J. Viral Hepat.     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-10-9     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9435672     Medline TA:  J Viral Hepat     Country:  -    
Other Details:
Languages:  ENG     Pagination:  766-774     Citation Subset:  -    
Copyright Information:
© 2012 Blackwell Publishing Ltd.
Affiliation:
Johann Wolfgang Goethe University Medical Center, Frankfurt am Main, Germany Fundación de Investigación De Diego, Santurce, PR, USA Gastroenterology and Hepatology, University of Pennsylvania, Philadelphia, PA, USA University of Paris, Clichy, France Hospital de Valencia, Valencia, Spain Gastroenterology and Hepatology, University of Palermo, Palermo, Italy Scripps Clinic, La Jolla, CA, USA Gastroenterology and Hepatology, San Giovanni Battista Hospital, Turin, Italy Digestive Diseases Institute of the Division of Gastroenterology, Hepatology, and Nutrition, Manhasset, NY, USA Liver Institute of Virginia, Bon Secours Health System, Newport News, VA, USA Roche, Nutley, NJ, USA Roche, Basel, Switzerland Department of Medicine and Hepatology, Henry Dunant Hospital, Athens, Greece.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Therapeutic potential of RNA interference: a new molecular approach to antiviral treatment for hepat...
Next Document:  Modulation of replication efficacy of the hepatitis C virus replicon Con1 by site-directed mutagenes...